There are 130 to 150 million people with chronic Hepatitis C all over the world from which almost 500 000 die each year because of cirrhosis or cancer. This disease does not spread through food, water, or casual contact.
Hepatitis C is a liver infection caused by a virus which spreads through the blood or body fluids of an infected person.
You can be contaminated:
There are different genotypes of Hepatitis C in the world. In Algeria the most common one is genotype 1. It is also the case in the United States, Canada or France for example.
New treatments for Hepatits C were developed by multinational companies, but at a very high cost. Therefore BEKER® Laboratories decided to search for affordable solutions for patients with Hepatitis C.
Thus, and following the success BEKER® Laboratories experienced by the development of the generic version of Sofosbuvir, Sofos® as well as the Sofosbuvir/Ledipasvir combination, Sofosled® with 100% proven efficacy, they enriched the pipeline by the development and production of the first ever sofosbuvir-daclatasvir combination, Sofosdac®.
Sofosdac® is the First and Only drug associating Sofosbuvir-Daclatasvir in ONE pill.
Sofosdac® is used to treat infection with hepatitis C in adults (18+), whatever the genotype. One daily pill during three months is sufficient to eliminate the Hepatitis C virus from your blood .
Sofosdac® is an interferon free which means that the patient does not have to combine this drug with interferon injections (Peginterferon). It can be taken alone or in combination with ribavirin. Please refer to your doctor for the details of your treatment.